Jiang Y.-L.,Jilin Provincial Liver and Gallbladder Diseases Hospital |
Shen K.-S.,Jilin Provincial Liver and Gallbladder Diseases Hospital |
Gao X.-J.,Jilin Provincial Liver and Gallbladder Diseases Hospital |
Li Y.-L.,Jilin Provincial Liver and Gallbladder Diseases Hospital |
Wu Y.-H.,Jilin Provincial Liver and Gallbladder Diseases Hospital
Chinese Journal of Biologicals | Year: 2011
Objective: To observe the curative effect of thymopentin (TP-5) on low replicating chronic hepatitis B (HB). Methods: Seventy-two chronic HB patients with HBV-DNA levels of less than 2000 IU/ml were divided into two groups. The 38 patients in trial group were injected i. m. with 1 mg of TP-5, once a day, while the 34 patients in control group were treated with Hugan Pian, an oral tablet, 3 times a day. A course consisted of 12 weeks, after which the patients were followed-up for 12 weeks. The patients in two groups were determined for HBV-DNA level by PCR, for serum markers of HB by chemiluminescent immunoassay, for liver function indexes by full automatic biochemical analyzer, and for liver fibrosis indexes by RIA. Results: The HBV-DNA negative conversion rates in trial group after treatment and follow-up were significantly higher than those in trial group (P < 0.05), The liver function and fibrosis function indexes in trial group after treatment were improved significantly as compared with those before teratment (P < 0.01 or P < 0.05), and showed significant difference with those in control group (P < 0.05). However, no significant difference was observed in the HBsAg-negative conversion rates of the two groups (P > 0.05). Conclusion: TP-5 promoted the negative conversion of HBV-DNA of patients with low-replicating, improved the function of injured liver and delayed the progress of liver fibrosis.